Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.

@article{Hiraga2009ImatinibMS,
  title={Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.},
  author={Toru Hiraga and Hiroaki Nakamura},
  journal={International journal of cancer},
  year={2009},
  volume={124 1},
  pages={
          215-22
        }
}
Imatinib mesylate (imatinib) is a potent and selective inhibitor of the tyrosine kinases, Bcr-Abl, c-Kit and platelet-derived growth factor receptors (PDGFRs). Recently, it has been reported that imatinib also targets the macrophage colony-stimulating factor (M-CSF) receptor c-Fms. M-CSF signals are essential for the differentiation of osteoclasts. Bone metastases of breast cancer are frequently associated with osteoclastic bone destruction. Furthermore, several lines of evidence suggest that… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Crosstalk between cancer cells and bone microenvironment in bone metastasis.

  • Biochemical and biophysical research communications
  • 2005
VIEW 4 EXCERPTS

Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2007
VIEW 1 EXCERPT